Skip to content

Prevalence of Myocarditis in Patients Suspected Myocardial Infarction With Non-Obstructive Coronary Arteries

Prevalence of Myocarditis in Patients Suspected Myocardial Infarction With Non-Obstructive Coronary Arteries

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06966531
Enrollment
148
Registered
2025-05-12
Start date
2025-05-05
Completion date
2027-04-01
Last updated
2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevalence of Myocarditis in MINOCA Patients

Keywords

Myocarditis, MINOCA, Normal coronary angiography

Brief summary

This study aims to determine the prevalence of myocarditis among patients suspected of having myocardial infarction with non-obstructive coronary arteries (MINOCA) and to analyze its clinical characteristics, diagnostic markers .

Detailed description

Acute myocardial infarction (AMI) remains the leading causes of high morbidity and mortality worldwide, Recently, a distinct population with myocardial infarction with nonobstructive coronary arteries (MINOCA) has been increasingly recognized because of the widespread use of coronary angiography. MINOCA occurs in 5%-10% of all AMI and they are younger and more often women compared to patients with AMI and obstructive coronary artery disease (CAD) , The underlying causes of MINOCA are manifold and may include plaque rupture or erosion, thromboembolism, coronary spasm, spontaneous dissection, microvascular dysfunction and supply/demand mismatch. Some non-ischemic diseases such as myocarditis may also mimic the presentation of MINOCA .Of note, several studies have found that the prognosis of MINOCA is not trivial and patients are still at considerable risks for long-term adverse cardiovascular (CV) events despite the optimal secondary prevention treatments \[\[6\], \[7\], \[8\], \[9\], \[10\]\]. Thus, it is of necessity and profound implications to find potential residual risk factors and improve prognosis in MINOCA population. Myocarditis is commonly caused by viral infections, but it can also be caused by bacterial infections, toxic substances, or autoimmune disorders . Myocarditis is more common in younger patients, although it affects patients of all ages. Fulminant myocarditis, although rare, can result in life-threatening cardiogenic shock . Diagnosis of myocarditis is made using CMRI characterized by the presence of diffuse myocardial edema on T2 and with myocardial biopsy . In a meta-analysis of five observational studies with available CMRI data, one-third of MINOCA patients had myocarditis. It was more common in younger patients and those with high C-reactive protein .

Interventions

PROCEDURECoronary angiography

distinguish between true MI with significant lesion and MINOCA with insignificant lesions (less than 50%)

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
17 Years to 80 Years

Inclusion criteria

* All patients; diagnosed with myocardial infarction with nonobstructive coronary arteries (MINOCA) * clinical symptoms * ECG : ischemic changes with or without ST segment elevation * Echocardiograpy : segmental wall motion abnormalities (SWMA) * positive cardiac enzymes * Coronary angiography: insignificant lesions ,the absence of culprit obstructive coronary artery disease (epicardial coronary artery stenosis ≥50%)

Exclusion criteria

* Significant coronary artery disease (\>50% stenosis) on angiography. * Prior history of myocarditis or cardiomyopathy. * Contraindications to CMR (e.g., pacemakers, severe renal dysfunction).

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of myocarditis in patients presenting with MINOCA, as diagnosed by CMR.1 yearsStudying The incidence of myocarditis in MINOCA patients

Contacts

Primary ContactAhmed Gamal Thabit Mohamed
ahmedgamal54011@gmail.com+201065476011

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026